4.8 Editorial Material

Dishonesty in scientific research

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 125, 期 11, 页码 3993-3996

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI84722

关键词

-

资金

  1. Eli Lilly and Company
  2. GlaxoSmithKline

向作者/读者索取更多资源

Fraudulent business practices, such as those leading to the Enron scandal and the conviction of Bernard Madoff, evoke a strong sense of public outrage. But fraudulent or dishonest actions are not exclusive to the realm of big corporations or to evil individuals without consciences. Dishonest actions are all too prevalent in everyone's daily lives, because people are constantly encountering situations in which they can gain advantages by cutting corners. Whether it's adding a few dollars in value to the stolen items reported on an insurance claim form or dropping outlier data points from a figure to make a paper sound more interesting, dishonesty is part of the human condition. Here, we explore how people rationalize dishonesty, the implications for scientific research, and what can be done to foster a culture of research integrity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据